Physician profile
Thomas Pohlman
NPI 1760597629
$754.23
in general payments reported to CMS, 2019-2025
15 companies · $395 in 2025
The $395 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $44.16 · 2023: $130 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $524.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vantive US Healthcare LLC | $173.94 | 2025 | Renal - Acute, Renal - Pd |
| Glaxosmithkline, LLC. | $169.39 | 2023-2025 | Benlysta |
| Mallinckrodt Enterprises LLC | $89.99 | 2019 | |
| Amgen INC. | $50.03 | 2025 | Krystexxa |
| Travere Therapeutics, INC. | $38.47 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $35.35 | 2019 | |
| Janssen Biotech, INC. | $31.85 | 2020 | |
| Vifor Pharma, INC. | $25.72 | 2025 | Veltassa |
| Pharmacosmos Therapeutics INC. | $24.77 | 2025 | Monoferric |
| Invivyd INC | $23.74 | 2025 | Pemgarda |
| Novartis Pharmaceuticals Corporation | $22.13 | 2019 | |
| Ardelyx, INC. | $21.65 | 2025 | Ibsrela |
| Ani Pharmaceuticals, INC. | $17.59 | 2025 | Purified Cortrophin Gel |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.30 | 2025 | |
| Horizon Therapeutics Plc | $12.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Pohlman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.